CHMP recommend licence extension for herpes zoster vaccine; recombinant, adjuvanted (Shingrix)

Following review, the CHMP now recommend Shingrix can be licensed for prevention of herpes zoster and post-herpetic neuralgia, in adults 50 years of age or older, and in adults 18 years of age or older at increased risk of herpes zoster.


European Medicines Agency